儿童间质性肺疾病与小儿肺纤维化临床试验的探索
儿童间质性肺疾病(chILD)是一组罕见的弥漫性肺疾病,病因异质且与肺发育相关,预后因病因不同可进展至肺移植或死亡。目前缺乏流行病学与自然史数据,治疗选择有限,尚无针对小儿肺纤维化的临床试验。本综述聚焦进展性chILD,强调亟需定义、检测和监测儿童纤维化的客观结局指标。
要点
- chILD为罕见异质性弥漫性肺疾病,预后因病因不同可进展至肺移植或死亡。
- 尚无针对小儿肺纤维化设计的药物临床试验,治疗选择有限。
- 亟需开发客观结局指标以定义、检测和监测儿童肺纤维化。
核心结论
- 进展性chILD领域缺乏客观结局指标,亟需开展针对小儿肺纤维化的临床试验。
研究设计与样本
- 本文为综述,聚焦进展性chILD及小儿肺纤维化临床试验需求。
主要发现
- chILD包含大量罕见诊断,流行病学与自然史数据有限。
- 部分chILD形式可进展至肺移植或死亡。
- 尚无使用抗纤维化药物治疗小儿人群的临床试验。
临床怎么用
- 临床需关注chILD进展性表型,探索客观纤维化监测指标。
局限性
- 综述未提供具体流行病学数据或临床试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Childhood interstitial lung disease (chILD) comprises a spectrum of rare diffuse lung disorders. chILD is heterogeneous in origin, with different disease manifestations occurring in the context of ongoing lung development. The large number of disorders in chILD, in combination with the rarity of each diagnosis, has hampered scientific and clinical progress within the field. Epidemiologic and natural history data are limited. The prognosis varies depending on the etiology, with some forms progressing to lung transplant or death. There are limited treatment options for patients with chILD. Although U.S. Food and Drug Administration-approved treatments are now available for adult patients with idiopathic pulmonary fibrosis, no clinical trials have been conducted in a pediatric population using agents designed to treat lung fibrosis. This review will focus on progressive chILD disorders and on the urgent need for meaningful objective outcome measures to define, detect, and monitor fibrosis in children.
引用
- Deterding RR, DeBoer EM, Cidon MJ, et al. Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019. PMID: 31322415. doi:10.1164/rccm.201903-0544CI
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。